RESUMO
BACKGROUND: The past 5 years have seen a proliferation of new treatments for atopic dermatitis (AD). We analyzed recent drug survival data for cyclosporine in this setting. Because the Spanish National Healthcare system requires patients with AD to be treated with cyclosporine before they can be prescribed other systemic treatments, drug survival for cyclosporine may be shorter than in other diseases. MATERIAL AND METHOD: Multicenter, observational, prospective cohort study using data from the Spanish Atopic Dermatitis Registry (BIOBADATOP). Data from the Spanish Registry of Systemic Treatments in Psoriasis (BIOBADADERM) were used to create a comparison cohort. RESULTS: We analyzed data for 130 patients with AD treated with cyclosporine (median drug survival, 1 year). Median cyclosporine survival in the psoriasis comparison group (150 patients) was 0.37 years. Drug survival was significantly longer in AD than in psoriasis (P<.001). CONCLUSION: Drug survival of cyclosporine in the BIOBADATOP registry is similar to that described in other series of patients with AD and longer than that observed in the BIOBADADERM psoriasis registry.
Assuntos
Dermatite Atópica , Psoríase , Humanos , Ciclosporina/uso terapêutico , Dermatite Atópica/tratamento farmacológico , Imunossupressores/uso terapêutico , Estudos Prospectivos , Psoríase/tratamento farmacológico , Sistema de Registros , Resultado do TratamentoRESUMO
BACKGROUND: In recent years, remarkable improvements in our understanding of atopic dermatitis (AD) have revolutionized treatment perspectives, but access to reliable data from clinical practice is essential. MATERIALS AND METHOD: The Spanish Atopic Dermatitis Registry, BIOBADATOP, is a prospective, multicenter database that collects information on patients of all ages with AD requiring systemic therapy with conventional or novel drugs. We analyzed the registry to describe patient characteristics, diagnoses, treatments, and adverse events (AEs). RESULTS: We studied data entries for 258 patients who had received 347 systemic treatments for AD. Treatment was discontinued in 29.4% of cases, mostly due to a lack of effectiveness (in 10.7% of cases). A total of 132 AEs were described during follow-up. Eighty-six AEs (65%) were linked to a systemic treatment, most commonly dupilumab (39AEs) and cyclosporine (38AEs). The most common AEs were conjunctivitis (11patients), headache (6), hypertrichosis (5), and nausea (4). There was 1severe AE (acute mastoiditis) associated with cyclosporine. CONCLUSIONS: Initial findings on AEs from the Spanish BIOBADATOP registry are limited by short follow-up times precluding comparisons or calculation of crude and adjusted incidence rates. At the time of our analysis, no severe AEs had been reported for novel systemic therapies. BIOBADATOP will help answer questions on the effectiveness and safety of conventional and novel systemic therapies in AD.
Assuntos
Dermatite Atópica , Humanos , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/epidemiologia , Estudos Prospectivos , Ciclosporina/uso terapêutico , Administração Cutânea , Sistema de Registros , Resultado do Tratamento , Índice de Gravidade de DoençaAssuntos
Humanos , Feminino , Pessoa de Meia-Idade , Hematoma/diagnóstico , Equimose/diagnóstico , Mãos , SíndromeAssuntos
Humanos , Feminino , Pessoa de Meia-Idade , Hematoma/diagnóstico , Equimose/diagnóstico , Mãos , SíndromeAssuntos
Humanos , Masculino , Adulto , Micose Fungoide/diagnóstico , Micose Fungoide/patologia , Biomarcadores , Antígenos CD4 , Antígenos CD8 , Fenótipo , BiópsiaAssuntos
Humanos , Masculino , Adulto , Micose Fungoide/diagnóstico , Micose Fungoide/patologia , Biomarcadores , Antígenos CD4 , Antígenos CD8 , Fenótipo , BiópsiaAssuntos
Osteopecilose/diagnóstico , Dermatopatias Genéticas/diagnóstico , Humanos , Lactente , MasculinoRESUMO
No disponible
Assuntos
Humanos , Masculino , Criança , Derme/patologia , Tecido Elástico/patologia , Pelve/patologia , Punho/patologia , Tecido Conjuntivo/patologia , Epífises/anormalidades , Remodelação Óssea/genéticaRESUMO
El dermatofibroma es una neoplasia cutánea común de crecimiento lento y comportamiento biológico benigno. Existen presentaciones clínicas poco frecuentes como el dermatofibroma atrófico, el dermatofibroma ulcerado y el dermatofibroma gigante que pueden plantear dudas diagnósticas. La extirpación es curativa, aunque en variantes profundas pueden quedar restos que predispongan a la recidiva. Presentamos un nuevo caso de dermatofibromagigante profundo extirpado mediante cirugía micrográfica de Mohs (AU)
Dermatofibroma is a frequent cutaneous neoplasm with slow growth and benign behaviour. There are uncommon clinical variants like atrophic dermatofibroma, ulcerated dermatofibroma and giant dermatofibroma which may cause diagnostic problems. Excision of the tumor is curative, although in deep types the removal can be incomplete, predisposing to recurrence. A new case of deep giant dermatofibroma removed by Mohs micrographicsurgery is reported (AU)